Table 3 Analysis of the oral manifestations of the Test Group during the COVID-19 pandemic
Parameters | Geographic tongue without exacerbation of the oral symptoms during the COVID-19 pandemic (N = 5) | Geographic tongue with exacerbation of the oral symptoms during the COVID-19 pandemic (N = 4) | p-valor (OR;CI) |
|---|---|---|---|
Gender | |||
Male | 1 (20.00%) | 0 (00.00%) | 0.34 |
Female | 4 (80.00%) | 4 (100.00%) | (3.0;0.094–95.25) |
Age | |||
Mean | 49,00 ± 9,70 | 29.50 ± 6.87 | 0.03 |
Symptoms for COVID19 | |||
Yes | 2 (40.00%) | 1 (25.00%) | 0.63 |
No | 3 (60.00%) | 3 (75.00%) | (2.00;0.11–35.83) |
Tested for COVID-19 | |||
Yes | 2 (40.00%) | 1 (25.00%) | 0.63 |
No | 3 (60.00%) | 3 (75.00%) | (2.0;0.11–35.83) |
Positive test for COVID-19 | |||
Yes | 2 (40.00%) | 1 (25.00%) | 0.63 |
No | 3 (60.00%) | 3 (75.00%) | (2.0;0.11–35.83) |
Medication use for COVID-19 | |||
Yes | 2 (40.00%) | 1 (25.00%) | 0.63 |
No | 3 (60.00%) | 3 (75.00%) | (2.0;0.11–35.83) |
Report of stress during the pandemic | |||
Yes | 1 (40.00%) | 4 (100.00%) | 0.02 |
No | 4 (60.00%) | 0 (00.00%) | (0.3; 0,00–1.18) |
Use of medication for GT symptoms | |||
Yes | 0 (00.00%) | 1 (25.00%) | 0.23 |
No | 5 (100.00%) | 3 (75.00%) | (0.21;0.00–6.82) |